Literature DB >> 22395993

Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.

Hooman Djaladat1, Craig Nichols, Siamak Daneshmand.   

Abstract

PURPOSE: To evaluate the clinicopathologic characteristics of patients undergoing adjuvant surgery during postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).
METHODS: From 2004 to 2010, 85 testicular cancer patients underwent PC-RPLND by a single surgeon (S.D.). A bilateral template approach was utilized with nerve-sparing technique whenever feasible. The clinicopathologic and outcome of patients who underwent removal of any organ or structure during PC-RPLND were reviewed.
RESULTS: Of 85 patients undergoing PC-RPLND, 28 (33%) required adjuvant procedures. Thirteen (15%) required vascular procedures including cavotomy/caval resection in 6, aortic resection in 8, common iliac vessels resection in 4, and renal vessels resection/reimplant in 2. Twelve patients (14%) required adjuvant nephrectomy (ten of 12 left-sided). There was one ureteral resection with appendiceal substitution, one partial duodenectomy, two cholecystectomy, two thoracotomies, four liver resection/biopsy, and one neck dissection. There were eight early complications (28%), including vocal cord paralysis, brachial plexus injury, lower extremities compartment syndrome, thigh numbness, upper gastrointestinal bleeding, retroperitoneal hematoma, and alcohol withdrawal. No perioperative death was reported. Retroperitoneal pathology revealed mature teratoma in 11 patients (39%), fibrosis in 8 (28%), and viable germ cell tumor (GCT) in 9 (32%). A total of 75, 82, and 66% of patients with fibrosis, teratoma, and viable GCT, respectively, had no evidence of recurrence at a mean follow-up of 18 months.
CONCLUSIONS: Many patients undergoing PC-RPLND require adjuvant surgery, including vascular procedures and nephrectomy. The excellent outcomes associated with low operative morbidity and mortality validates such aggressive surgical approaches performed by experienced surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22395993     DOI: 10.1245/s10434-012-2284-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.

Authors:  Shiyu Tong; Minfeng Chen; Xiongbing Zu; Yuan Li; Wei He; Ye Lei; Wentao Liu; Lin Qi
Journal:  Int Urol Nephrol       Date:  2013-09-01       Impact factor: 2.370

2.  [Management of complications after residual tumor resection for metastatic testicular cancer].

Authors:  A Lusch; M Zaum; C Winter; P Albers
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 3.  Residual tumor resection (RTR).

Authors:  A Lusch; P Albers
Journal:  World J Urol       Date:  2016-12-21       Impact factor: 4.226

Review 4.  Surgical strategies for postchemotherapy testis cancer.

Authors:  Saum Ghodoussipour; Siamak Daneshmand
Journal:  Transl Androl Urol       Date:  2020-01

5.  Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.

Authors:  S Considine; R Heaney; R Conroy; J A Thornhill
Journal:  Ir J Med Sci       Date:  2015-12-21       Impact factor: 1.568

6.  Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.

Authors:  Hiten D Patel; Gregory A Joice; Zeyad R Schwen; Alice Semerjian; Ridwan Alam; Arnav Srivastava; Mohamad E Allaf; Phillip M Pierorazio
Journal:  World J Urol       Date:  2017-10-12       Impact factor: 4.226

7.  [Diagnosis and treatment of nonseminomatous germ cell tumors].

Authors:  S Krege
Journal:  Urologe A       Date:  2013-12       Impact factor: 0.639

8.  [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].

Authors:  P Paffenholz; D Pfister; A Heidenreich
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

Review 9.  Primary and post-chemotherapy robotic retroperitoneal lymph node dissection for testicular cancer: a review.

Authors:  Shagnik Ray; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Transl Androl Urol       Date:  2020-04

10.  Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Testicular Cancer: A Single Center Experiences.

Authors:  Mohamadreza Nowroozi; Mohsen Ayati; Amir Arbab; Hassan Jamshidian; Hamidreza Ghorbani; Hassan Niroomand; Mohsen Taheri Mahmoodi; Erfan Amini; Sohrab Salehi; Hamid Hakima; Farid Fazeli; Saeid Haghdani; Alireza Ghadian
Journal:  Nephrourol Mon       Date:  2015-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.